Why the GlaxoSmithKline dividend makes me nervous

The current GlaxoSmithKline dividend yield is over 5%. Our writer explains why, despite that, he will not be adding it to his income portfolio.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Earning passive income is an important objective in my investing. A lot of the shares I consider buying are attractive to me at least in part for their income potential. That is one of the reasons I have occasionally been eyeing pharmaceutical firm GlaxoSmithKline (LSE: GSK) for my portfolio over the past couple of years. But the GlaxoSmithKline dividend, offering a yield of 5.1%, is not quite as appealing to me as it initially seems. Here is what makes me nervous – and has held me back from adding the company to my portfolio.

Lack of dividend growth

A company’s dividend history is not necessarily indicative of what it will do in future. But it can help me understand how a company has been thinking about its dividend. At surface level, the 5%+ dividend on offer at GlaxoSmithKline would be an attractive addition to my portfolio. It is higher than the dividend yield offered by many other blue chip companies.

However, the dividend has been flat for years. The last increase was in 2014. Although the 80p per share dividend remains generous, what concerns me is why the company has repeatedly decided not to raise its dividend. I feel it suggests that the business has not been improving enough to make the board feel comfortable with spending more money on a dividend.

Plan for the GlaxoSmithKline dividend to fall

The lack of confidence to grow the dividend is not what most concerns me here. It is what comes next.

GlaxoSmithKline is routinely described as a pharmaceutical business. But it also has a large consumer goods business selling non-prescription items often found in chemists. These include household names such as toothpaste Aquafresh and painkiller Panadol. It is easy to understand how those two businesses developed in tandem. GlaxoSmithKline now plans to spin off its consumer goods business into a different company. It hopes to unlock more shareholder value by letting the two businesses sharpen their focus in their own particular areas.

But this is set to be bad news for dividends, at least in the short term. The company has said that the pharma business expects to pay 45p per share in dividends next year. The dividend for the consumer goods business will depend on its directors. But it is expected to come in at around 7p per share. That would mean a total annual dividend of 52p per current share, compared to 80p now. So, if I bought GlaxoSmithKline shares for my portfolio today, although the current yield is 5.1%, the prospective yield for next year is a much less attractive 3.3%.

I will not buy GlaxoSmithKline for yield

So, after years of a flat dividend, GlaxoSmithKline is likely to see a big dividend cut next year. A reorganisation meant to unlock shareholder value will in fact probably result in lower shareholder distributions, at least in the beginning.

I think that shows a lack of determined focus on the part of the company’s management when it comes to maintaining or growing shareholder returns. That concerns me, because it makes me wonder if increasing the dividend will be a priority in future. With the yield set to fall and a questionable focus on the importance of dividends to shareholders, I do not plan to add GlaxoSmithKline to my portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Christopher Ruane has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »